Paolo Mascagni

This inventor holds 21 USPTO granted patents and 3 published patent applications, plus 7 CIPO patents and 7 EPO patents, primarily in Pharmaceutical Chemistry. Top assignee: Italfarmaco Spa. Active years: 1999-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Paolo Mascagni. Retrieved from https://idiyas.com/inventor/paolo-mascagni

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 (Patent Applications = 3)

% Patents Active = 95.2

CIPO Patents = 7

EPO Patents = 7 (Patent Applications = 7)

Average Co-Inventor Count = 3.7

ph-index = 4

Forward Citations = 83(Granted Patents)

Location History:

Sesto S. Giovanni, IT (1999 - 2000)
Cinisello Balsamo, IT (1999 - 2007)
Villasanta (MI), IT (2012)
Milan, IT (2008 - 2014)
Villasanta, IT (2006 - 2018)
Alicante, ES (2020)

Company Filing History:

21 out of 49

Italfarmaco Spa

patents

Years Active: 1999-2020

Loading Chart...

Areas of Expertise:

Oral Suspensions

Antitumor Activity

Histone Deacetylase Inhibitors

Muscular Dystrophy

Somatostatin Analogues

Hydroxamic Acid Derivatives

Anti-inflammatory Compounds

HIV Infections

Sustained Release

Peptides

Cyclodextrin Complexes

Oligopeptides

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10688047 - Physically and chemically stable oral suspensions of givinostat (2020-06-23),

2. 10590101 - Benzo-N-hydroxy amide compounds having antitumor activity (2020-03-17),

3. 9867799 - Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy (2018-01-16),

4. 9522127 - Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes (2016-12-20),

5. 9421184 - Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy (2016-08-23),

6. 8937152 - Non-selective somatostatin analogues (2015-01-20),

7. 8765150 - Riluzole aqueous suspensions (2014-07-01),

8. 8637702 - Derivatives of N-hydroxybenzamide for treating HIV infections (2014-01-28),

9. 8227515 - Use of hydroxamic acid derivatives for the preparation of anti-tumour medicaments (2012-07-24),

10. 8217079 - Method for treating Philadelphia-negative myeloproliferative syndromes (2012-07-10),

11. 7635788 - Alpha-amino acid derivatives with antiinflammatory activity (2009-12-22),

12. 7427620 - Azole derivative useful as antifungal agents with reduced interaction with metabolic cytochromes (2008-09-23),

13. 7329689 - Monohydrate hydrochloride of the 4-hydroxycarbamoyl-phenyl)-carbamic acid (6-diethylaminomethyl-naphtalen-2-yl) ester (2008-02-12),

14. 7235689 - Hydroxamic acid derivatives having anti-inflammatory action (2007-06-26),

15. 7157099 - Sustained release pharmaceutical compositions for the parenteral administration of hydrophilic compounds (2007-01-02),

Title: **Innovative Contributions of Paolo Mascagni in Pharmaceutical Patents**

Introduction

Paolo Mascagni, a notable inventor based in Villasanta, IT, has made significant contributions to the field of pharmaceuticals, holding a remarkable 21 patents. His work primarily focuses on formulations that enhance the stability and efficacy of therapeutic compounds, showcasing his commitment to advancing medical science through innovation.

Latest Patents

Among Paolo Mascagni's latest inventions are two notable patents that highlight his expertise. The first patent pertains to "Physically and chemically stable oral suspensions of givinostat." This innovation involves the development of aqueous suspensions containing Givinostat and/or its pharmaceutically acceptable salts or derivatives. These formulations incorporate a wetting agent and/or a density-imparting agent, ensuring suitability for oral administration with systemic therapeutic action.

The second patent introduces "Benzo-N-hydroxy amide compounds having antitumor activity." This invention describes new compounds that exhibit significant inhibitory activity on the proliferation of tumor cells, particularly targeting cancer stem cells. Such advancements could potentially lead to more effective cancer therapies.

Career Highlights

Paolo Mascagni is currently affiliated with Italfarmaco S.p.A., a prominent company in the pharmaceutical industry. Throughout his career, he has endeavored to create innovative solutions that address critical healthcare challenges, solidifying his reputation as an influential inventor.

Collaborations

Mascagni's innovative journey is complemented by valuable collaborations with his colleagues Flavio Leoni and Massimo Pinori. Their combined expertise and effort contribute to the success and implementation of groundbreaking pharmaceutical solutions, enhancing the impact of their collective work.

Conclusion

Paolo Mascagni exemplifies the spirit of innovation in the pharmaceutical sector. With 21 patents to his name, his contributions not only demonstrate his ingenuity but also offer promising avenues for future research and development in therapeutic formulations. The ongoing collaboration with fellow experts further amplifies his impact on the fight against diseases, particularly in the realm of oncology.

Profile summary based on public USPTO records.